Table 6.
Comparison of 10-year fracture probabilities calculated using the FRAX, and candidates for pharmacological intervention by the FRAX criteria in patients with knee osteoarthritis and healthy controls, except those with previous fractures and male patients.
| Osteoarthritis n = 194 |
Healthy Controls n = 194 |
p Value | |
|---|---|---|---|
| FRAX calculations, Mean ± SD | |||
| Major osteoporotic fracture probability with femur BMD | 6.4 ± 2.9 | 6.0 ± 2.6 | 0.104 |
| Hip fracture probability with femur BMD | 1.8 ± 1.8 | 1.6± 1.6 | 0.090 |
| Major osteoporotic fracture probability without femur BMD | 7.5 ± 3.0 | 6.8 ± 2.2 | <0.0001 ** |
| Hip fracture probability without femur BMD | 2.7 ± 2.1 | 2.3 ± 1.6 | <0.0001 ** |
| Candidates for pharmacological intervention, n (%) | |||
| FRAX with femur BMD | 37 (19.1) | 34 (17.5) | 0.691 |
| FRAX without femur BMD | 74 (38.1) | 64 (33.0) | 0.025 * |
* p < 0.05, ** p < 0.005. Statistical analysis was performed using paired t-test and McNemar’s test. FRAX, fracture risk assessment tool; SD, standard deviation; BMD, bone mineral density.